Minireview: Hey U(PS): Metabolic and proteolytic homeostasis linked via AMPK and the ubiquitin proteasome system

Molecular Endocrinology

Volumn 28, Issue 10, 2014, Pages 1602-1615

  Ronnebaum, Sarah M ^a   Patterson, Cam ^a   Schisler, Jonathan C ^a,b  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b WEILL CORNELL MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATROGIN 1; DEUBIQUITINASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; LAFORIN; MALIN; MUSCLE RING FINGER 1 PROTEIN; PROTEASOME; REGULATOR PROTEIN; S PHASE KINASE ASSOCIATED PROTEIN 2; SUMO PROTEIN; UBIQUITIN; UBIQUITIN PROTEIN LIGASE E3; UNCLASSIFIED DRUG;

AMINO ACID METABOLISM; ARTICLE; COMPLEX FORMATION; ENERGY CONSUMPTION; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME REGULATION; ENZYME STRUCTURE; HOMEOSTASIS; HUMAN; METABOLIC REGULATION; NONHUMAN; NUTRIENT; PROTEIN DEGRADATION; PROTEIN STABILITY; SIGNAL TRANSDUCTION; SUMOYLATION; UBIQUITINATION; ANIMAL; ENERGY METABOLISM; METABOLISM; PHYSIOLOGY;

AMP-ACTIVATED PROTEIN KINASES; ANIMALS; ENERGY METABOLISM; HOMEOSTASIS; HUMANS; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTEOLYSIS; UBIQUITIN; UBIQUITINATION;

EID: 84907676869     PISSN: 08888809     EISSN: 19449917     Source Type: Journal    
DOI: 10.1210/me.2014-1180     Document Type: Article

References (157)

1. Beg ZH, Allmann DW, Gibson DM. Modulation of 3-hydroxy-3- methylglutaryl coenzyme A reductase activity with cAMP and wth protein fractions of rat liver cytosol. Biochem Biophys Res Commun. 1973;54(4):1362-1369.
2. Carlson CA, Kim KH. Regulation of hepatic acetyl coenzyme A carboxylase by phosphorylation and dephosphorylation. J Biol Chem. 1973;248(1):378-380.
3. Carling D, Clarke PR, Zammit VA, Hardie DG. Purification and characterization of the AMP-activated protein kinase. Copurification of acetyl-CoA carboxylase kinase and 3-hydroxy-3-methylglutaryl- CoA reductase kinase activities. Eur J Biochem. 1989; 186(1-2):129-136.
4. Hardie DG, Ross FA, Hawley SA. AMPK: a nutrient and energy sensor that maintains energy homeostasis. Nat Rev Mol Cell Biol. 2012;13(4):251-262.
5. Hardie DG. AMPK: a target for drugs and natural products with effects on both diabetes and cancer. Diabetes. 2013;62(7):2164-2172.
6. Zaha VG, Young LH. AMP-activated protein kinase regulation and biological actions in the heart. Circ Res. 2012;111(6):800-814.
7. Ronnett GV, Ramamurthy S, Kleman AM, Landree LE, Aja S. AMPK in the brain: its roles in energy balance and neuroprotection. J Neurochem. 2009;109(suppl 1):17-23.
8. Crute BE, Seefeld K, Gamble J, Kemp BE, Witters LA. Functional domains of the α1 catalytic subunit of the AMP-activated protein kinase. J Biol Chem. 1998;273(52):35347-35354.
9. Salt I, Celler JW, Hawley SA, et al. AMP-activated protein kinase: greater AMP dependence, and preferential nuclear localization, of complexes containing the α2 isoform. Biochem J. 1998;334(pt 1):177-187.
10. Hudson ER, Pan DA, James J, et al. A novel domain in AMPactivated protein kinase causes glycogen storage bodies similar to those seen in hereditary cardiac arrhythmias. Curr Biol. 2003; 13(10):861-866.
11. Thornton C, Snowden MA, Carling D. Identification of a novel AMP-activated protein kinase β subunit isoform that is highly expressed in skeletal muscle. J Biol Chem. 1998;273(20):12443-12450.
12. Bateman A. The structure of a domain common to archaebacteria and the homocystinuria disease protein. Trends Biochem Sci. 1997;22(1):12-13.
13. Scott JW, Hawley SA, Green KA, et al. CBS domains form energysensing modules whose binding of adenosine ligands is disrupted by disease mutations. J Clin Invest. 2004;113(2):274-284.
14. Cheung PC, Salt IP, Davies SP, Hardie DG, Carling D. Characterization of AMP-activated protein kinase γ-subunit isoforms and their role in AMP binding. Biochem J. 2000;346(pt 3):659-669.
15. Li J, Coven DL, Miller EJ, Hu X, et al. Activation of AMPK α- and γ-isoform complexes in the intact ischemic rat heart. Am J Physiol Heart Circ Physiol. 2006;291(4):H1927-H1934.
16. Mahlapuu M, Johansson C, Lindgren K, et al. Expression profiling of the γ-subunit isoforms of AMP-activated protein kinase suggests a major role for γ3 in white skeletal muscle. Am J Physiol Endocrinol Metab. 2004;286(2):E194-E200.
17. Ferrer A, Caelles C, Massot N, Hegardt FG. Activation of rat liver cytosolic 3-hydroxy-3-methylglutaryl coenzyme A reductase kinase by adenosine 5¢-monophosphate. Biochem Biophys Res Commun. 1985;132(2):497-504.
18. Hawley SA, Davison M, Woods A, et al. Characterization of the AMP-activated protein kinase kinase from rat liver and identification of threonine 172 as the major site at which it phosphorylates AMP-activated protein kinase. J Biol Chem. 1996;271(44): 27879-27887.
19. Shaw RJ, Kosmatka M, Bardeesy N, et al. The tumor suppressor LKB1 kinase directly activates AMP-activated kinase and regulates apoptosis in response to energy stress. Proc Natl Acad Sci USA. 2004;101(10):3329-3335.
20. Hawley SA, Pan DA, Mustard KJ, et al. Calmodulin-dependent protein kinase kinase-β is an alternative upstream kinase for AMPactivated protein kinase. Cell Metab. 2005;2(1):9-19.
21. Hawley SA, Selbert MA, Goldstein EG, Edelman AM, Carling D, Hardie DG. 5¢-AMP activates the AMP-activated protein kinase cascade, and Ca2+/calmodulin activates the calmodulin-dependent protein kinase I cascade, via three independent mechanisms. J Biol Chem. 1995;270(45):27186-27191.
22. Momcilovic M, Hong SP, Carlson M. Mammalian TAK1 activates Snf1 protein kinase in yeast and phosphorylates AMP-activated protein kinase in vitro. J Biol Chem. 2006;281(35):25336-25343.
23. Xie M, Zhang D, Dyck JR, et al. A pivotal role for endogenous TGF-β-activated kinase-1 in the LKB1/AMP-activated protein kinase energy-sensor pathway. Proc Natl Acad Sci USA. 2006; 103(46):17378-17383.
24. Davies SP, Helps NR, Cohen PT, Hardie DG. 5¢-AMP inhibits dephosphorylation, as well as promoting phosphorylation, of the AMP-activated protein kinase. Studies using bacterially expressed human protein phosphatase-2C a and native bovine protein phosphatase- 2AC. FEBS Lett. 1995;377(3):421-425.
25. Gowans GJ, Hawley SA, Ross FA, Hardie DG. AMP is a true physiological regulator of AMP-activated protein kinase by both allosteric activation and enhancing net phosphorylation. Cell Metab. 2013;18(4):556-566.
26. Drew BG, Fidge NH, Gallon-Beaumier G, Kemp BE, Kingwell BA. High-density lipoprotein and apolipoprotein AI increase endothelialNO synthase activity by protein association and multisite phosphorylation. Proc Natl Acad Sci USA. 2004;101(18):6999-7004.
27. Minokoshi Y, Kim YB, Peroni OD, et al. Leptin stimulates fattyacid oxidation by activating AMP-activated protein kinase. Nature. 2002;415(6869):339-343.
28. Yamauchi T, Kamon J, Minokoshi Y, et al. Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMPactivated protein kinase. Nat Med. 2002;8(11):1288-1295.
29. Horman S, Vertommen D, Heath R, et al. Insulin antagonizes ischemia-induced Thr172 phosphorylation of AMP-activated protein kinase α-subunits in heart via hierarchical phosphorylation of Ser485/491. J Biol Chem. 2006;281(9):5335-5340.
30. Gleason CE, Lu D, Witters LA, Newgard CB, Birnbaum MJ. The role of AMPK and mTOR in nutrient sensing in pancreatic β-cells. J Biol Chem. 2007;282(14):10341-10351.
31. Steinberg GR, Michell BJ, van Denderen BJ, et al. Tumor necrosis factor α-induced skeletal muscle insulin resistance involves suppression of AMP-kinase signaling. Cell Metab. 2006;4(6):465-474.
32. Sullivan JE, Brocklehurst KJ, Marley AE, Carey F, Carling D, Beri RK. Inhibition of lipolysis and lipogenesis in isolated rat adipocytes with AICAR, a cell-permeable activator of AMP-activated protein kinase. FEBS Lett. 1994;353(1):33-36.
33. Zhou G, Myers R, Li Y, et al. Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest. 2001; 108(8):1167-1174.
34. Hawley SA, Gadalla AE, Olsen GS, Hardie DG. The antidiabetic drug metformin activates the AMP-activated protein kinase cascade via an adenine nucleotide-independent mechanism. Diabetes. 2002;51(8):2420-2425.
35. Foretz M, Hébrard S, Leclerc J, et al. Metformin inhibits hepatic gluconeogenesis in mice independently of the LKB1/AMPK pathway via a decrease in hepatic energy state. J Clin Invest. 2010; 120(7):2355-2369.
36. Miller RA, Chu Q, Xie J, Foretz M, Viollet B, Birnbaum MJ. Biguanides suppress hepatic glucagon signalling by decreasing production of cyclic AMP. Nature. 2013;494(7436):256-260.
37. Fryer LG, Parbu-Patel A, Carling D. The anti-diabetic drugs rosiglitazone and metformin stimulate AMP-activated protein kinase through distinct signaling pathways. J Biol Chem. 2002; 277(28):25226-25232.
38. Nawrocki AR, Rajala MW, Tomas E, et al. Mice lacking adiponectin show decreased hepatic insulin sensitivity and reduced responsiveness to peroxisome proliferator-activated receptor γ agonists. J Biol Chem. 2006;281(5):2654-2660.
39. Steinberg GR, Kemp BE. AMPK in health and disease. Physiol Rev. 2009;89(3):1025-1078.
40. Bain J, Plater L, Elliott M, et al. The selectivity of protein kinase inhibitors: a further update. Biochem J. 2007;408(3):297-315.
41. Russell RR 3rd, Bergeron R, Shulman GI, Young LH. Translocation of myocardial GLUT-4 and increased glucose uptake through activation of AMPK by AICAR. Am J Physiol. 1999;277(2 pt 2):H643-H649.
42. Luiken JJ, Coort SL, Willems J, et al. Contraction-induced fatty acid translocase/CD36 translocation in rat cardiac myocytes is mediated through AMP-activated protein kinase signaling. Diabetes. 2003;52(7):1627-1634.
43. Marsin AS, Bertrand L, Rider MH, et al. Phosphorylation and activation of heart PFK-2 by AMPK has a role in the stimulation of glycolysis during ischaemia. Curr Biol. 2000;10(20):1247-1255.
44. Kudo N, Barr AJ, Barr RL, Desai S, Lopaschuk GD. High rates of fatty acid oxidation during reperfusion of ischemic hearts are associated with a decrease in malonyl-CoA levels due to an increase in 5¢ -AMP-activated protein kinase inhibition of acetyl-CoA carboxylase. J Biol Chem. 1995;270(29):17513-17520.
45. Samari HR, Seglen PO. Inhibition of hepatocytic autophagy by adenosine, aminoimidazole-4-carboxamide riboside, and N6- mercaptopurine riboside. Evidence for involvement of amp-activated protein kinase. J Biol Chem. 1998;273(37):23758-23763.
46. Carling D, Hardie DG. The substrate and sequence specificity of the AMP-activated protein kinase. Phosphorylation of glycogen synthase and phosphorylase kinase. Biochim Biophys Acta. 1989;1012(1):81-86.
47. Henin N, Vincent MF, Gruber HE, Van den Berghe G. Inhibition of fatty acid and cholesterol synthesis by stimulation of AMPactivated protein kinase. FASEB J. 1995;9(7):541-546.
48. Sim AT, Hardie DG. The low activity of acetyl-CoA carboxylase in basal and glucagon-stimulated hepatocytes is due to phosphorylation by the AMP-activated protein kinase and not cyclic AMPdependent protein kinase. FEBS Lett. 1988;233(2):294-298.
49. Bolster DR, Crozier SJ, Kimball SR, Jefferson LS. AMP-activated protein kinase suppresses protein synthesis in rat skeletal muscle through down-regulated mammalian target of rapamycin (mTOR) signaling. J Biol Chem. 2002;277(27):23977-23980.
50. Horman S, Browne G, Krause U, et al. Activation of AMP-activated protein kinase leads to the phosphorylation of elongation factor 2 and an inhibition of protein synthesis. Curr Biol. 2002; 12(16):1419-1423.
51. Inoki K, Zhu T, Guan KL. TSC2 mediates cellular energy response to control cell growth and survival. Cell. 2003;115(5):577-590.
52. Banko MR, Allen JJ, Schaffer BE, et al. Chemical genetic screen for AMPKα2 substrates uncovers a network of proteins involved in mitosis. Mol Cell. 2011;44(6):878-892.
53. Hardie DG. AMP-activated protein kinase: an energy sensor that regulates all aspects of cell function. Genes Dev. 2011;25(18): 1895-1908.
54. Hardie DG, Ashford ML. AMPK: regulating energy balance at the cellular and whole body levels. Physiology (Bethesda). 2014; 29(2):99-107.
55. Hardie DG, Hawley SA, Scott JW. AMP-activated protein kinase- development of the energy sensor concept. J Physiol. 2006;574(pt 1):7-15.
56. Feng Z, Hu W, de Stanchina E, et al. The regulation of AMPK β1, TSC2, and PTEN expression by p53: stress, cell and tissue specificity, and the role of these gene products in modulating the IGF- 1-AKT-mTOR pathways. Cancer Res. 2007;67(7):3043-3053.
57. Rock KL, Gramm C, Rothstein L, et al. Inhibitors of the proteasome block the degradation of most cell proteins and the generation of peptides presented on MHC class I molecules. Cell. 1994; 78(5):761-771.
58. Komander D, Rape M. The ubiquitin code. Annu Rev Biochem. 2012;81:203-229.
59. Lee JO, Lee SK, Kim N, et al. E3 ubiquitin ligase, WWP1, interacts with AMPKα2 and down-regulates its expression in skeletal muscle C2C12 cells. J Biol Chem. 2013;288(7):4673-4680.
60. Wang P, Zhang RY, Song J, et al. Loss of AMP-activated protein kinase--α2 impairs the insulin-sensitizing effect of calorie restriction in skeletal muscle. Diabetes. 2012;61(5):1051-1061.
61. Qi J, Gong J, Zhao T, et al. Downregulation of AMP-activated protein kinase by Cidea-mediated ubiquitination and degradation in brown adipose tissue. EMBO J. 2008;27(11):1537-1548.
62. Rubio T, Vernia S, Sanz P. Sumoylation of AMPKβ2 subunit enhances AMP-activated protein kinase activity. Mol Biol Cell. 2013;24(11):1801-1811, S1801-1804.
63. Wang W, Lv N, Zhang S, et al. Cidea is an essential transcriptional coactivator regulating mammary gland secretion of milk lipids. Nat Med. 2012;18(2):235-243.
64. Xu L, Zhou L, Li P. CIDE proteins and lipid metabolism. Arterioscler Thromb Vasc Biol. 2012;32(5):1094-1098.
65. Zhou Z, Yon Toh S, Chen Z, et al. Cidea-deficient mice have lean phenotype and are resistant to obesity. Nat Genet. 2003;35(1): 49-56.
66. Dai Q, Zhang C, Wu Y, et al. CHIP activates HSF1 and confers protection against apoptosis and cellular stress. EMBO J. 2003; 22(20):5446-5458.
67. Min JN, Whaley RA, Sharpless NE, Lockyer P, Portbury AL, Patterson C. CHIP deficiency decreases longevity, with accelerated aging phenotypes accompanied by altered protein quality control. Mol Cell Biol. 2008;28(12):4018-4025.
68. Schisler JC, Rubel CE, Zhang C, Lockyer P, Cyr DM, Patterson C. CHIP protects against cardiac pressure overload through regulation of AMPK. J Clin Invest. 2013;123(8):3588-3599.
69. Gaude H, Aznar N, Delay A, et al. Molecular chaperone complexes with antagonizing activities regulate stability and activity of the tumor suppressor LKB1. Oncogene. 2012;31(12):1582-1591.
70. Cordoba M, Rodriguez-Quiroga S, Gatto EM, Alurralde A, Kauffman MA. Ataxia plus myoclonus in a 23-year-old patient due to STUB1 mutations. Neurology. 2014.
71. Depondt C, Donatello S, Simonis N, et al. Autosomal recessive cerebellar ataxia of adult onset due to STUB1 mutations. Neurology. 2014;82(19):1749-1750.
72. Shi CH, Schisler JC, Rubel CE, et al. Ataxia and hypogonadism caused by the loss of ubiquitin ligase activity of the U box protein CHIP. Hum Mol Genet. 2014;23(4):1013-1024.
73. Shi Y, Wang J, Li JD, et al. Identification of CHIP as a novel causative gene for autosomal recessive cerebellar ataxia. PLoS One. 2013;8(12):e81884.
74. Synofzik M, Gonzalez MA, Lourenco CM, et al. PNPLA6 mutations cause Boucher-Neuhauser and Gordon Holmes syndromes as part of a broad neurodegenerative spectrum. Brain. 2014; 137(pt 1):69-77.
75. Spasic MR, Callaerts P, Norga KK. AMP-activated protein kinase (AMPK) molecular crossroad for metabolic control and survival of neurons. Neuroscientist. 2009;15(4):309-316.
76. Lupher ML Jr, Andoniou CE, Bonita D, Miyake S, Band H. The c-Cbl oncoprotein. Int J Biochem Cell Biol. 1998;30(4):439-444.
77. Saltiel AR, Pessin JE. Insulin signaling in microdomains of the plasma membrane. Traffic. 2003;4(11):711-716.
78. Molero JC, Jensen TE, Withers PC, et al. c-Cbl-deficient mice havereduced adiposity, higher energy expenditure, and improved peripheral insulin action. J Clin Invest. 2004;114(9):1326-1333.
79. Molero JC, Turner N, Thien CB, Langdon WY, James DE, Cooney GJ. Genetic ablation of the c-Cbl ubiquitin ligase domain results in increased energy expenditure and improved insulin action. Diabetes. 2006;55(12):3411-3417.
80. Ito T, Ando H, Suzuki T, et al. Identification of a primary target of thalidomide teratogenicity. Science. 2010;327(5971):1345-1350.
81. Lee KM, Jo S, Kim H, Lee J, Park CS. Functional modulation of AMP-activated protein kinase by cereblon. Biochim Biophys Acta. 2011;1813(3):448-455.
82. Burger A, Amemiya Y, Kitching R, Seth AK. Novel RING E3 ubiquitin ligases in breast cancer. Neoplasia. 2006;8(8):689-695.
83. Buac D, Kona FR, Seth AK, Dou QP. Regulation of metformin response by breast cancer associated gene 2. Neoplasia. 2013; 15(12):1379-1390.
84. Al-Hakim AK, Zagorska A, Chapman L, Deak M, Peggie M, Alessi DR. Control of AMPK-related kinases by USP9X and atypical Lys(29)/Lys(33)-linked polyubiquitin chains. Biochem J. 2008;411(2):249-260.
85. Li R, Wan B, Zhou J, et al. APC/C(Cdh1) targets brain-specific kinase 2 (BRSK2) for degradation via the ubiquitin-proteasome pathway. PLoS One. 2012;7(9):e45932.
86. Zhou J, Wan B, Li R, et al. Jab1 interacts with brain-specific kinase 2 (BRSK2) and promotes its degradation in the ubiquitinproteasome pathway. Biochem Biophys Res Commun. 2012; 422(4):647-652.
87. Wood JD, Yuan J, Margolis RL, et al. Atrophin-1, the DRPLA gene product, interacts with two families ofWWdomain-containing proteins. Mol Cell Neurosci. 1998;11(3):149-160.
88. Peth A, Nathan JA, Goldberg AL. The ATP costs and time required to degrade ubiquitinated proteins by the 26 S proteasome. J Biol Chem. 2013;288(40):29215-29222.
89. Clague MJ, Urbé S. Ubiquitin: same molecule, different degradation pathways. Cell. 2010;143(5):682-685.
90. Hedbacker K, Carlson M. SNF1/AMPK pathways in yeast. Front Biosci. 2008;13:2408-2420.
91. Wilson MA, Koutelou E, Hirsch C, et al. Ubp8 and SAGA regulate Snf1 AMP kinase activity. Mol Cell Biol. 2011;31(15):3126-3135.
92. Al-Hakim AK, Goransson O, Deak M, et al. 14-3-3 cooperates with LKB1 to regulate the activity and localization of QSK and SIK. J Cell Sci. 2005;118(pt 23):5661-5673.
93. Simpson-Lavy KJ, Johnston M. SUMOylation regulates the SNF1 protein kinase. Proc Natl Acad Sci USA. 2013;110(43):17432-17437.
94. Uzunova K, Göttsche K, Miteva M, et al. Ubiquitin-dependent proteolytic control of SUMO conjugates. J Biol Chem. 2007; 282(47):34167-34175.
95. Wang S, Xu J, Song P, Viollet B, Zou MH. In vivo activation of AMP-activated protein kinase attenuates diabetes-enhanced degradation of GTP cyclohydrolase I. Diabetes. 2009;58(8):1893-1901.
96. Viana R, Aguado C, Esteban I, et al. Role of AMP-activated protein kinase in autophagy and proteasome function. Biochem Biophys Res Commun. 2008;369(3):964-968.
97. Wang S, Zhang M, Liang B, et al. AMPKα2 deletion causes aberrant expression and activation of NAD(P)H oxidase and consequent endothelial dysfunction in vivo: role of 26S proteasomes. Circ Res. 2010;106(6):1117-1128.
98. Xu J, Wang S, Viollet B, Zou MH. Regulation of the proteasome by AMPK in endothelial cells: the role of O-GlcNAc transferase (OGT). PLoS One. 2012;7(5):e36717.
99. Moreno D, Viana R, Sanz P. Two-hybrid analysis identifies PSMD11, a non-ATPase subunit of the proteasome, as a novel interaction partner of AMP-activated protein kinase. Int J Biochem Cell Biol. 2009;41(12):2431-2439.
100. Song P, Wang S, He C, Liang B, Viollet B, Zou MH. AMPKα2 deletion exacerbates neointima formation by upregulating Skp2 in vascular smooth muscle cells. Circ Res. 2011;109(11):1230-1239.
101. Song P, Zhou Y, Coughlan KA, et al. Adenosine monophosphateactivated protein kinase-α2 deficiency promotes vascular smooth muscle cell migration via S-phase kinase-associated protein 2 upregulation and E-cadherin downregulation. Arterioscler Thromb Vasc Biol. 2013;33(12):2800-2809.
102. Polyak K, Kato JY, Solomon MJ, et al. p27Kip1, a cyclin-Cdk inhibitor, links transforming growth factor-β and contact inhibition to cell cycle arrest. Genes Dev. 1994;8(1):9-22.
103. Carrano AC, Eytan E, Hershko A, Pagano M. SKP2 is required for ubiquitin-mediated degradation of the CDK inhibitor p27. Nat Cell Biol. 1999;1(4):193-199.
104. Short JD, Dere R, Houston KD, et al. AMPK-mediated phosphorylation of murine p27 at T197 promotes binding of 14-3-3 proteins and increases p27 stability. Mol Carcinog. 2010;49(5):429-439.
105. Bodine SC, Latres E, Baumhueter S, et al. Identification of ubiquitin ligases required for skeletal muscle atrophy. Science. 2001; 294(5547):1704-1708.
106. Arya R, Kedar V, Hwang JR, et al. Muscle ring finger protein-1 inhibits PKC[Î] activation and prevents cardiomyocyte hypertrophy. J Cell Biol. 2004;167(6):1147-1159.
107. Li HH, Kedar V, Zhang C, et al. Atrogin-1/muscle atrophy F-box inhibits calcineurin-dependent cardiac hypertrophy by participating in an SCF ubiquitin ligase complex. J Clin Invest. 2004;114(8): 1058-1071.
108. Willis MS, Ike C, Li L, Wang DZ, Glass DJ, Patterson C. Muscle ring finger 1, but not muscle ring finger 2, regulates cardiac hypertrophy in vivo. Circ Res. 2007;100(4):456-459.
109. Gomes MD, Lecker SH, Jagoe RT, Navon A, Goldberg AL. Atrogin-1, a muscle-specific F-box protein highly expressed during muscle atrophy. Proc Natl Acad Sci USA. 2001;98(25): 14440-14445.
110. Krawiec BJ, Nystrom GJ, Frost RA, Jefferson LS, Lang CH. AMPactivated protein kinase agonists increase mRNA content of the muscle-specific ubiquitin ligases MAFbx and MuRF1 in C2C12 cells. Am J Physiol Endocrinol Metab. 2007;292(6):E1555-E1567.
111. Nakashima K, Yakabe Y. AMPK activation stimulates myofibrillar protein degradation and expression of atrophy-related ubiquitin ligases by increasing FOXO transcription factors in C2C12 myotubes. Biosci Biotechnol Biochem. 2007;71(7):1650-1656.
112. Sandri M, Sandri C, Gilbert A, et al. Foxo transcription factors induce the atrophy-related ubiquitin ligase atrogin-1 and cause skeletal muscle atrophy. Cell. 2004;117(3):399-412.
113. Stitt TN, Drujan D, Clarke BA, et al. The IGF-1/PI3K/Akt pathway prevents expression of muscle atrophy-induced ubiquitin ligases by inhibiting FOXO transcription factors. Mol Cell. 2004; 14(3):395-403.
114. Festuccia WT, Laplante M, Brûlé S, et al. Rosiglitazone-induced heart remodelling is associated with enhanced turnover of myofibrillar protein and mTOR activation. J Mol Cell Cardiol. 2009; 47(1):85-95.
115. Nystrom GJ, Lang CH. Sepsis and AMPK activation by AICAR differentially regulate FoxO-1, -3 and -4 mRNA in striated muscle. Int J Clin Exp Med. 2008;1(1):50-63.
116. Tabony AM, Yoshida T, Galvez S, et al. Angiotensin II upregulates protein phosphatase 2Cα and inhibits AMP-activated protein kinase signaling and energy balance leading to skeletal muscle wasting. Hypertension. 2011;58(4):643-649.
117. Greer EL, Oskoui PR, Banko MR, et al. The energy sensor AMPactivated protein kinase directly regulates the mammalian FOXO3 transcription factor. J Biol Chem. 2007;282(41):30107-30119.
118. Tong JF, Yan X, Zhu MJ, Du M. AMP-activated protein kinase enhances the expression of muscle-specific ubiquitin ligases despite its activation of IGF-1/Akt signaling in C2C12 myotubes. J Cell Biochem. 2009;108(2):458-468.
119. Baskin KK, Taegtmeyer H. AMP-activated protein kinase regulates E3 ligases in rodent heart. Circ Res. 2011;109(10):1153-1161.
120. Minassian BA, Lee JR, Herbrick JA, et al. Mutations in a gene encoding a novel protein tyrosine phosphatase cause progressive myoclonus epilepsy. Nat Genet. 1998;20(2):171-174.
121. Chan EM, Young EJ, Ianzano L, et al. Mutations in NHLRC1 cause progressive myoclonus epilepsy. Nat Genet. 2003;35(2): 125-127.
122. Girard JM, Turnbull J, Ramachandran N, Minassian BA. Progressive myoclonus epilepsy. Handb Clin Neurol. 2013;113:1731-1736.
123. Fernández-Sánchez ME, Criado-García O, Heath KE, et al. Laforin, the dual-phosphatase responsible for Lafora disease, interacts with R5 (PTG), a regulatory subunit of protein phosphatase-1 that enhances glycogen accumulation. Hum Mol Genet. 2003;12(23): 3161-3171.
124. Tagliabracci VS, Turnbull J, Wang W, et al. Laforin is a glycogen phosphatase, deficiency of which leads to elevated phosphorylation of glycogen in vivo. Proc Natl Acad Sci USA. 2007;104(49): 19262-19266.
125. Wang J, Stuckey JA, Wishart MJ, Dixon JE. A unique carbohydrate binding domain targets the lafora disease phosphatase to glycogen. J Biol Chem. 2002;277(4):2377-2380.
126. Romá-Mateo C, Solaz-Fuster Mdel C, Gimeno-Alcañiz JV, et al. Laforin, a dual-specificity phosphatase involved in Lafora disease, is phosphorylated at Ser25 by AMP-activated protein kinase. Biochem J. 2011;439(2):265-275.
127. Solaz-Fuster MC, Gimeno-Alcañiz JV, Ros S, et al. Regulation of glycogen synthesis by the laforin-malin complex is modulated by the AMP-activated protein kinase pathway. Hum Mol Genet. 2008;17(5):667-678.
128. Worby CA, Gentry MS, Dixon JE. Malin decreases glycogen accumulation by promoting the degradation of protein targeting to glycogen (PTG). J Biol Chem. 2008;283(7):4069-4076.
129. Vernia S, Solaz-Fuster MC, Gimeno-Alcañiz JV, et al. AMP-activated protein kinase phosphorylates R5/PTG, the glycogen targeting subunit of the R5/PTG-protein phosphatase 1 holoenzyme, and accelerates its down-regulation by the laforin-malin complex. J Biol Chem. 2009;284(13):8247-8255.
130. Moreno D, Towler MC, Hardie DG, Knecht E, Sanz P. The laforinmalin complex, involved in Lafora disease, promotes the incorporation of K63-linked ubiquitin chains into AMP-activated protein kinase β subunits. Mol Biol Cell. 2010;21(15):2578-2588.
131. Roma-Mateo C, Moreno D, Vernia S, et al. Lafora disease E3- ubiquitin ligase malin is related to TRIM32 at both the phylogenetic and functional level. BMC Evol Biol. 2011;11:225.
132. Cohen S, Zhai B, Gygi SP, Goldberg AL. Ubiquitylation by Trim32 causes coupled loss of desmin, Z-bands, and thin filaments in muscle atrophy. J Cell Biol. 2012;198(4):575-589.
133. Gentry MS, Worby CA, Dixon JE. Insights into Lafora disease: malin is an E3 ubiquitin ligase that ubiquitinates and promotes the degradation of laforin. Proc Natl Acad Sci USA. 2005;102(24): 8501-8506.
134. Singh PK, Singh S, Ganesh S. The laforin-malin complex negatively regulates glycogen synthesis by modulating cellular glucose uptake via glucose transporters. Mol Cell Biol. 2012;32(3):652-663.
135. Almaça J, Kongsuphol P, Hieke B, et al. AMPK controls epithelial Na(+) channels through Nedd4-2 and causes an epithelial phenotype when mutated. Pflugers Arch. 2009;458(4):713-721.
136. Bhalla V, Oyster NM, Fitch AC, et al. AMP-activated kinase inhibits the epithelial Na+ channel through functional regulation of the ubiquitin ligase Nedd4-2. J Biol Chem. 2006;281(36):26159-26169.
137. Carattino MD, Edinger RS, Grieser HJ, et al. Epithelial sodium channel inhibition by AMP-activated protein kinase in oocytes and polarized renal epithelial cells. J Biol Chem. 2005;280(18): 17608-17616.
138. Sopjani M, Alesutan I, Dërmaku-Sopjani M, et al. Down-regulation of Na+ -coupled glutamate transporter EAAT3 and EAAT4 by AMP-activated protein kinase. J Neurochem. 2010;113(6): 1426-1435.
139. Alesutan I, Föller M, Sopjani M, et al. Inhibition of the heterotetrameric K+ channel KCNQ1/KCNE1 by the AMP-activated protein kinase. Mol Membr Biol. 2011;28(2):79-89.
140. Alesutan I, Munoz C, Sopjani M, et al. Inhibition of Kir2.1 (KCNJ2) by the AMP-activated protein kinase. Biochem Biophys Res Commun. 2011;408(4):505-510.
141. Alzamora R, Gong F, Rondanino C, et al. AMP-activated protein kinase inhibits KCNQ1 channels through regulation of the ubiquitin ligase Nedd4-2 in renal epithelial cells. Am J Physiol Renal Physiol. 2010;299(6):F1308-F1319.
142. Andersen MN, Krzystanek K, Jespersen T, Olesen SP, Rasmussen HB. AMP-activated protein kinase downregulates Kv7.1 cell surface expression. Traffic. 2012;13(1):143-156.
143. Mia S, Munoz C, Pakladok T, et al. Downregulation of Kv1.5 K channels by the AMP-activated protein kinase. Cell Physiol Biochem. 2012;30(4):1039-1050.
144. Lang F, Eylenstein A, Shumilina E. Regulation of Orai1/STIM1 by the kinases SGK1 and AMPK. Cell Calcium. 2012;52(5):347-354.
145. King JD Jr, Fitch AC, Lee JK, et al. AMP-activated protein kinase phosphorylation of the R domain inhibits PKA stimulation of CFTR. Am J Physiol Cell Physiol. 2009;297(1):C94-C101.
146. Kongsuphol P, Cassidy D, Hieke B, et al. Mechanistic insight into control of CFTR by AMPK. J Biol Chem. 2009;284(9):5645-5653.
147. Klein H, Garneau L, Trinh NT, et al. Inhibition of the KCa3.1 channels by AMP-activated protein kinase in human airway epithelial cells. Am J Physiol Cell Physiol. 2009;296(2):C285-C295.
148. Wyatt CN, Mustard KJ, Pearson SA, et al. AMP-activated protein kinase mediates carotid body excitation by hypoxia. J Biol Chem. 2007;282(11):8092-8098.
149. Sopjani M, Bhavsar SK, Fraser S, Kemp BE, Foller M, Lang F. Regulation of Na+ -coupled glucose carrier SGLT1 by AMP-activated protein kinase. Mol Membr Biol. 2010;27(2-3):137-144.
150. Andersen MN, Rasmussen HB. AMPK: a regulator of ion channels. Commun Integr Biol. 2012;5(5):480-484.
151. Lang F, Foller M. Regulation of ion channels and transporters by AMPactivated kinase (AMPK). Channels (Austin). 2014;8(1):20-28.
152. Chen D, Frezza M, Schmitt S, Kanwar J, Dou QP. Bortezomib as the first proteasome inhibitor anticancer drug: current status and future perspectives. Curr Cancer Drug Targets. 2011;11(3):239-253.
153. Na LX, Zhang YL, Li Y, et al. Curcumin improves insulin resistance in skeletal muscle of rats. Nutr Metab Cardiovasc Dis. 2011; 21(7):526-533.
154. Shao W, Yu Z, Chiang Y, et al. Curcumin prevents high fat diet induced insulin resistance and obesity via attenuating lipogenesis in liver and inflammatory pathway in adipocytes. PLoS One. 2012;7(1):e28784.
155. Weisberg SP, Leibel R, Tortoriello DV. Dietary curcumin significantly improves obesity-associated inflammation and diabetes in mouse models of diabesity. Endocrinology. 2008;149(7):3549-3558.
156. Chuengsamarn S, Rattanamongkolgul S, Luechapudiporn R, Phisalaphong C, Jirawatnotai S. Curcumin extract for prevention of type 2 diabetes. Diabetes Care. 2012;35(11):2121-2127.
157. Stapleton D, Mitchelhill KI, Gao G, et al. Mammalian AMP-activated protein kinase subfamily. J Biol Chem. 1996;271(2):611-614.